Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content
Chronic Kidney Disease (CKD) Surveillance System

Indicator Details: Prevalence of ESRD by U.S. Statea,b
Data Sources
Stratification and Year Choices:


Multi-year: Use Quintiles Across All Years

Single-year: Use Quintiles For Each Year
Prevalence of ESRD by U.S. State 2015 2428.8 2212.6 2203.6 2200.1 2198.5 2197.1 2191.9 2169.9 2131.4 2129.9 2072.6 2069.5 2034.2 2029.5 2028.9 2017.5 2013.8 2012.5 1991.1 1985.1 1982.3 1958.9 1945.9 1935.7 1922.1 1914.6 1905.6 1905.1 1903.6 1876.7 1870.6 1868.2 1856.7 1817.4 1764.4 1761.3 1733.6 1700.1 1648.2 1631.7 1576.3 1568.8 1546.5 1485.4 1470.8 1442.5 1387.5 1251.7 1185.8 1175.6 1155.7

a Adapted from the 2017 USRDS Annual Data Report (United States Renal Data System, 2017).

b Estimates show the prevalence per million state residents.

The United States Renal Data System (USRDS) is national registry of all patients treated for end-stage renal disease in the United States. It is sponsored by the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) and the Centers for Medicare & Medicaid Services (CMS) that reports prevalence of all treated ESRD in the United States. U.S. population denominators are determined through U.S. Census data. Tables from the USRDS annual report (United States Renal Data System, 2017) are publicly available for download.
Description of MeasurePrevalence of end-stage renal disease (ESRD) (Stage 5)
Type of Data SourcePublic
Health Care System DataNo
Regional or National?National
Demographic GroupMedicare-eligible U.S. citizens with ESRD-related claims with known age, race/ethnicity, and gender
NumeratorDecember 31 point prevalent counts of patients reported to have ESRD without loss-to-follow up or recovery of renal function
DenominatorU.S. resident population from U.S. census from corresponding year
Definition of CKDStage 5, <15 ml/min/1.73 m² with Medicare-eligibility for ESRD-related treatment
Primary Data Source IndicatorNumber of U.S. patients reported to have ESRD, as indicated by treatment (dialysis or functioning transplant)
Primary Indicator Method of MeasurementClaims
Frequency of Measurement (Primary)Annual (cross-sectional)
U.S. Region Covered by Primary VariableAll
Period Currently Available2015
Pending Data2016
Additional Data Items of InterestYear, age (from date of birth), race/ethnicity (from Medicare 2728 form), gender (from Medicare 2728 form), assigned cause of ESRD (from Medicare 2728 form)
Limitations of IndicatorOnly those who are Medicare-eligible are captured & eligibility may be delayed
Analytical ConsiderationsDenominators change with missing stratification variables
ESRD prevalence varied widely by state in 2015, with values of >2,400 per million in the District of Columbia and ≤1,300 per million in Alaska, Vermont, Maine, and New Hampshire.
Chart Explanation: ESRD prevalence varied by state. In 2015, the highest prevalence was found in the District of Columbia (>2,400 per million population); 9 other states also had relatively high prevalence, at >2,100 per million population (Illinois, South Dakota, Wisconsin, Missouri, Ohio, Indiana, Michigan, Mississippi, and Pensylvania). 

The states with the lowest prevalence of ESRD were New Hampshire (1,156 per million), Maine (1,176 per million) and Vermont (1,186 per million).

Many of the U.S. states have shown minor decreases in prevalence since 2015, particuarly in states with the highest and lowest prevalences. Nonetheless, the Midwest region developed to having consisntently the highest prevalence of ESRD, relative to other regions, with most states having >2,200 per million in the population. In addition, the Southwest region continues to have a high prevalence, but with most states having <2,100 per million prevalence in the population.
References and Sources:
  • United States Renal Data System. 2017 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2017.
Suggested Citation:
Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System—United States.